SW626 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Intestine cancer cell lines |
| Organism |
Human |
| Donor History |
Colon adenocarcinoma |
| Growth Properties |
Adherent |
| Growth Conditions |
Culture medium: DMEM:Ham's F12 (1:1) ,w: 3.1 g/L Glucose ,w: 2.5 mM L-Glutamine ,w: 15 mM HEPES ,w: 0.5 mM Sodium pyruvate ,w: 1.2 g/L NaHCO3 (Cytion article number 820400a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
SW626 is a human ovarian cancer cell line established from an adult patient with serous cystadenocarcinoma of the ovary. It has been widely utilized as a model for epithelial ovarian cancer (EOC), particularly for studying tumor biology, drug response, and molecular heterogeneity in high-grade serous carcinoma. Histologically, the SW626 cell line retains characteristics consistent with its serous adenocarcinoma origin and exhibits tumorigenic potential when xenografted into immunocompromised mice, producing solid tumors that recapitulate features of the primary neoplasm.
Genomic profiling of SW626 reveals common alterations frequently observed in ovarian cancers, including disruptions in key regulatory pathways such as TP53 and PI3K/AKT. Molecular analyses have shown that SW626 carries chromosomal aberrations and gene expression patterns representative of high-grade serous ovarian cancer, making it a relevant model for investigating oncogenic signaling, therapeutic vulnerabilities, and resistance mechanisms. The cell line has been included in large-scale cancer genomics projects, where it contributes to drug screening platforms and comparative studies with other ovarian cancer models, helping to define molecular subtypes and inform precision oncology approaches.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

